Xilio Therapeutics Q3 2026 Results: Net Loss of $5.95M, Loss Narrows
Xilio Therapeutics reported 7,063,982 shares of common stock outstanding as of November 6, 2026. The company highlights its reliance on strategic collaborations with AbbVie and Gilead, and notes potential gross proceeds of $36.2 million in Q4 2026 from the exercise of Series C warrants.
- Key figure
- Net loss $5.95M